|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTDSPL2 |
Gene summary for CTDSPL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTDSPL2 | Gene ID | 51496 |
| Gene name | CTD small phosphatase like 2 | |
| Gene Alias | HSPC058 | |
| Cytomap | 15q15.3-q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024R5Q8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51496 | CTDSPL2 | CCI_2 | Human | Cervix | CC | 2.31e-06 | 6.48e-01 | 0.5249 |
| 51496 | CTDSPL2 | CCI_3 | Human | Cervix | CC | 1.50e-04 | 5.14e-01 | 0.516 |
| 51496 | CTDSPL2 | LZE2T | Human | Esophagus | ESCC | 9.58e-03 | 4.25e-01 | 0.082 |
| 51496 | CTDSPL2 | LZE4T | Human | Esophagus | ESCC | 4.65e-09 | 2.00e-01 | 0.0811 |
| 51496 | CTDSPL2 | LZE7T | Human | Esophagus | ESCC | 1.02e-02 | 2.12e-01 | 0.0667 |
| 51496 | CTDSPL2 | LZE8T | Human | Esophagus | ESCC | 1.64e-03 | 2.17e-01 | 0.067 |
| 51496 | CTDSPL2 | LZE20T | Human | Esophagus | ESCC | 1.47e-03 | 6.40e-02 | 0.0662 |
| 51496 | CTDSPL2 | LZE24T | Human | Esophagus | ESCC | 5.81e-09 | 1.96e-01 | 0.0596 |
| 51496 | CTDSPL2 | P1T-E | Human | Esophagus | ESCC | 3.68e-12 | 4.06e-01 | 0.0875 |
| 51496 | CTDSPL2 | P2T-E | Human | Esophagus | ESCC | 7.63e-26 | 3.01e-01 | 0.1177 |
| 51496 | CTDSPL2 | P4T-E | Human | Esophagus | ESCC | 5.95e-20 | 3.86e-01 | 0.1323 |
| 51496 | CTDSPL2 | P5T-E | Human | Esophagus | ESCC | 2.02e-14 | 2.56e-01 | 0.1327 |
| 51496 | CTDSPL2 | P8T-E | Human | Esophagus | ESCC | 1.73e-21 | 4.84e-01 | 0.0889 |
| 51496 | CTDSPL2 | P9T-E | Human | Esophagus | ESCC | 4.29e-14 | 2.55e-01 | 0.1131 |
| 51496 | CTDSPL2 | P10T-E | Human | Esophagus | ESCC | 9.24e-30 | 5.26e-01 | 0.116 |
| 51496 | CTDSPL2 | P11T-E | Human | Esophagus | ESCC | 4.01e-05 | 1.77e-01 | 0.1426 |
| 51496 | CTDSPL2 | P12T-E | Human | Esophagus | ESCC | 1.80e-19 | 3.92e-01 | 0.1122 |
| 51496 | CTDSPL2 | P15T-E | Human | Esophagus | ESCC | 1.17e-20 | 4.41e-01 | 0.1149 |
| 51496 | CTDSPL2 | P16T-E | Human | Esophagus | ESCC | 1.12e-21 | 3.39e-01 | 0.1153 |
| 51496 | CTDSPL2 | P19T-E | Human | Esophagus | ESCC | 1.42e-09 | 4.02e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:00468229 | Cervix | CC | regulation of nucleocytoplasmic transport | 31/2311 | 106/18723 | 2.68e-06 | 7.87e-05 | 31 |
| GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
| GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
| GO:00511689 | Cervix | CC | nuclear export | 38/2311 | 154/18723 | 1.86e-05 | 3.46e-04 | 38 |
| GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
| GO:00468248 | Cervix | CC | positive regulation of nucleocytoplasmic transport | 19/2311 | 62/18723 | 1.11e-04 | 1.40e-03 | 19 |
| GO:00468259 | Cervix | CC | regulation of protein export from nucleus | 12/2311 | 30/18723 | 1.23e-04 | 1.53e-03 | 12 |
| GO:00071786 | Cervix | CC | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2311 | 355/18723 | 2.39e-04 | 2.67e-03 | 67 |
| GO:00066116 | Cervix | CC | protein export from nucleus | 17/2311 | 57/18723 | 3.61e-04 | 3.75e-03 | 17 |
| GO:00163117 | Cervix | CC | dephosphorylation | 73/2311 | 417/18723 | 1.23e-03 | 9.87e-03 | 73 |
| GO:0006913110 | Esophagus | ESCC | nucleocytoplasmic transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:0051169110 | Esophagus | ESCC | nuclear transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:003238618 | Esophagus | ESCC | regulation of intracellular transport | 243/8552 | 337/18723 | 3.20e-23 | 7.25e-21 | 243 |
| GO:0051168110 | Esophagus | ESCC | nuclear export | 126/8552 | 154/18723 | 1.88e-20 | 2.65e-18 | 126 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTDSPL2 | SNV | Missense_Mutation | novel | c.164T>G | p.Phe55Cys | p.F55C | Q05D32 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.817) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CTDSPL2 | SNV | Missense_Mutation | novel | c.670C>T | p.Arg224Cys | p.R224C | Q05D32 | protein_coding | tolerated(0.11) | possibly_damaging(0.446) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CTDSPL2 | deletion | Frame_Shift_Del | novel | c.371_381delNNNNNNNNNNN | p.Lys125Ter | p.K125* | Q05D32 | protein_coding | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| CTDSPL2 | SNV | Missense_Mutation | c.1210N>C | p.Asp404His | p.D404H | Q05D32 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| CTDSPL2 | SNV | Missense_Mutation | c.1210G>T | p.Asp404Tyr | p.D404Y | Q05D32 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| CTDSPL2 | SNV | Missense_Mutation | novel | c.488N>T | p.Ser163Leu | p.S163L | Q05D32 | protein_coding | deleterious(0.02) | probably_damaging(0.946) | TCGA-ZJ-AAXD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| CTDSPL2 | SNV | Missense_Mutation | c.220A>C | p.Ile74Leu | p.I74L | Q05D32 | protein_coding | tolerated_low_confidence(0.49) | benign(0) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CTDSPL2 | SNV | Missense_Mutation | c.155N>A | p.Ile52Asn | p.I52N | Q05D32 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CTDSPL2 | SNV | Missense_Mutation | c.56N>A | p.Arg19His | p.R19H | Q05D32 | protein_coding | tolerated_low_confidence(0.18) | benign(0.005) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| CTDSPL2 | SNV | Missense_Mutation | c.1117N>T | p.Arg373Trp | p.R373W | Q05D32 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-4001-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |